Sculptra Dermik Laboratories - Treatment for Facial Lipoatrophy in HIV Patients
Sculptra is used for the restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus.Posted: August 2004
Related articles
- FDA Approves Sculptra Aesthetic, a Facial Injectable for Correction of Nasolabial Folds and Other Facial Wrinkles - July 29, 2009
- Sculptra From Dermik Laboratories Receives Recommendation For Approval With Conditions From FDA Advisory Panel - March 26, 2004
- Aventis' Dermik Laboratories Announces FDA Acceptance of Filing For Sculptra to Treat Facial Lipoatrophy - February 6, 2004
Sculptra (injectable poly-L-lactic acid) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
